The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease. Understanding the molecular biology behind castration-resistant prostate cancer has led to more treatment options, but there are still no definite conclusions about which specific drug best treats patients - maximum suppression of cancer growth while minimizing side effects. The PROMOTE study explores the genetic characteristics of each tumor to predict these treatment paradigms for the future, resulting in more effective and less toxic options for patients. Our long-term goal is to improve treatments for men with advanced prostate cancer by using genomic sequencing to increase life span and quality of life. We also will uncover novel vulnerable targets in the cancer genome that may provide new drug therapies. PARTICIPATION Eligible participants are men: <ul> <li>With castration-resistant prostate cancer or prostate cancer not responding to hormone treatments</li> <li>About to begin abiraterone acetate therapy</li> <li>Agreeable to undergoing two tumor biopsies</li> </ul> During the study, participants travel to Mayo Clinic for an initial biopsy (before beginning abiraterone acetate) and a second biopsy approximately three months later. The cell tissue collected is analyzed to identify gene alterations in the tumor that could eventually be targeted with treatments. Tissue is preserved for future research. Participants can continue to be treated by their local cancer care team during this period and beyond. In addition, the Mayo team carefully monitors participants' cancer via follow-up studies and the genetic signature of tumors that were biopsied so that patients may benefit from future treatments.

PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of    Castration Resistant Prostate Cancer (CRPC) Patients Treated with    Abiraterone Acetate

Prostatic Neoplasms, Castration-Resistant study with RNA-Seq, SNP Genotypes (NGS) + 1 more data on dbGaP (88 participants)

phs001141 — PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of    Castration Resistant Prostate Cancer (CRPC) Patients Treated with    Abiraterone Acetate

PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate

Description

Applying For Access

Summary